Abstract:Objective: To study the efficacy and safety of cefprozil in tereatment of community acquired respiratory tract infections (CARTI). Method: An open, comparative, multicenter clinical trial was performed in 9 hospitals in Beijing, Shanghai, Wuhan and Dalian from April 2000 to September 2000. The clinical and bacteriological efficacy and safety were compared between cefprozil and cefaclor in treating mild to moderate CARTI. Results: A total of 417 patiens was enrolled: upper respiratory tract infections (URTI) 227, lower respiratory tract infections (LRTI) 190. Among them, 222 patients were assigned to cefprozil group while 195 patients to cefaclor group. Sex, age, fever, WBC and PMN, bacteria spectrum were similar between groups (P > 0.05). The regimens were as follows: cefrozil 500mg qd for URTI or 500mg bid for LRTI, cefaclor 250mg tid for URTL or 500mg tid for LRTI. The duration was 7 - 14d for all patients. The clinical efficacy of cefprozil, in URTI and LRTI was 94.7% and 92.2%, higher than that of cefaclor (91.5% and 83.0%). Successful bacteriological eradication of the causative pathogen in both URTI and LRTI was 90.8% in cefprozil and 85.5% in cefaclor. However, statistic analysis did not show significant differences (P > 0.05). Sensitivity testing showed that Streptococcus pneumoniae, beta-hemolytic Streptococci, Haemophilus influenzae and Parainfluenzae, Staphylococcus aureus and Klebsiella pneumoniae isolated in these CARTI were sensitive to cefprozil and cefaclor with the rate 90.9 % - 100.0% and 91.9% - 100.0% respectively. Side effects in both groups were low with 5.9% for cefprozil and 4.6% for cefaclor (P > 0.05). Liver and kidney function tests in following up patients showed normal in both cefprozil and cefaclor groups (292 and 295 patients respective) at the end of treatment. Conclusion: Due to its good antibacteria activity and clinical efficacy, high bacteriological eradication and low side effect rates, cefprozil should become first line antimicrobial agent in treating mild to moderate CARTI.

Cefaclor in treatment of secondary lower respiratory tract infections in chronic obstructive pulmonary diseases

Cefaclor Sustained Release Vs Cefprozil in Treatment of Acute Exacerbation of Chronic Bronchitis

Clinical Study of Cefprozil in Treatment of Respiratory Tract Infections

Comparative study on cefprozil and cefaclor in the treatment of respiratory tract infections

A randomized controlled clinical study on cefprozil and cefuroxime axetil in the treatment of low respiratory tract bacterial infections

Comparative study on cefdinir and cefaclor in the treatment of patients with mild to moderate bacterial community acquired pneumonia

Clinical efficacy of cefixime in the treatment of children with respiratory tract infection

Efficacy of cefepime on the treatment of senile with lower respiratory infections

Clinical evaluation of cefepime in treatment of lower respir atory tract bacterial infections

Clinical Trial on Augmentin Against Acute Exacerbation of Chronic Bronchitis (AECB) in Adults

Short-term and Long-Term Outcomes of Moxifloxacin Treatment in Acute Exacerbations of COPD

Domestic Cefepime in the Treatment of Moderate to Severe Respiratory Infection

Clinical efficacy of cefpiramide for lower respiratory tract infection

A clinical trial on ceftriaxone 1g daily in treatme nt of lower respiratory tract infection

Curative Effect Analysis of Cefoxitin Sodium in the Treatment of Senile Bacterial Lower Respiratory Tract Infection

Clinical Trial on Gatifloxacin Against Acute Exacerbation of Chronic Bronchitis (AECB) in Adults

A Randomized,controlled Clinical Trial of Levofloxacin Versus Ceftriaxone and Azithromycin in the Treatment of Community-Acquired Lower Respiratory Tract Infections

Clinical Study of Inhaled Ambroxol in the Adjunctive Treatment of Lower Respiratory Tract Infection Induced by Pseudomonas Aeruginosa

Clinical Evaluation of Effect and Safety of Cefepime on 383 Patients with Moderate or Severe Infection

Clinical evaluation on the empirical treatment of community acquired pneumonia

Efficacy of Cefoperazone/sulbactam 2∶1 Vs Cefoperazone/sulb Actam 1∶1 in Treatment of Lower Respiratory Tract Infections